Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Today we learn whether AI might help hasten the development of n-of-1 therapies (hint: not yet), explore why the FDA hasn’t offered Orange Book guidance on drug-device combinations, and talk about CRISPR. A lot.

advertisement

The need-to-know this morning

  • AC Immune has sold global licensing rights to an experimental immunotherapy for Alzheimer’s disease to the Japanese drugmaker Takeda. AC Immune received $100 million from Takeda for the therapy, called ACI-24.060, and is eligible for another $2.1 billion in future payments.
  • Merck reported negative results from an interim analysis of a Phase 3 study involving the use of its experimental anti-TIGIT antibody as an adjuvant treatment for patients with high-risk melanoma.
  • Cancer drug developer OnKure is going public via a reverse merger with Reneo Pharma.

AI might not yet help develop ‘n-of-1’ treatments

Can AI be used to help create “n-of-1” treatments for the rarest of genetic diseases? The jury’s still out, a new study suggests.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.